PhRMA blasts Indian court's ruling against drug patent

PhRMA rebuked India's Supreme Court for refusing to grant Novartis patent protection on its cancer medicine Glivec. The ruling is "another example of what I would characterize as a deteriorating innovation environment in India," said Chip Davis, PhRMA's executive vice president of advocacy. "It is critically important that India promote a policy environment that supports continued research and development of new medicines for the health of patients in India and worldwide," PhRMA CEO and President John J. Castellani said.

View Full Article in:

Hill, The · New York Times (tiered subscription model), The · Reuters